1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Ligand soars on GSK win for new Promacta use in HCV patients

 
• By Donna Young

Shares of Ligand Pharmaceuticals soared as high as 17.4% on 19 November on word the US FDA gave its blessing for the company's partner, GlaxoSmithKline, to market Promacta (eltrombopag) as a treatment for thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C virus (HCV) intended to allow them to initiate and maintain interferon-based therapy.

Shares of Ligand Pharmaceuticals soared as high as 17.4% on 19 November on word the US FDA gave its blessing for the company's partner, GlaxoSmithKline, to market Promacta (eltrombopag) as a treatment for thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C virus (HCV) intended to allow them to initiate and maintain interferon-based therapy.

Shares of Ligand closed at $19.07 on 19 November, a gain of $2.40, or 14.4%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapeutic Category

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.